Abstract. Melanoma is a malignant tumor with high degree of malignancy, metastasis and high mortality. The etiology of melanoma has not been fully elucidated, and there is no effective drug for the complete treatment of melanoma. In recent years, many traditional Chinese herbal medicines have played an important role in clinical treatment and experimental research on cancer. As a natural product, fangchinoline has the characteristics of enhancing immune function, low toxicity and good liver protection features, so it is considered to be a new type of anticancer drug. In the present study, we found that fangchinoline has inhibitory effects on the proliferation and metastasis of A375 and A875 cells in a concentration-dependent manner. Fangchinoline inhibited the proliferation of A375 and A875 cell activity with IC₅₀ values of 12.41 and 16.20 µM. We also found that fangchinoline could significantly reduce the phosphorylation of Focal adhesion kinase (FAK). In summary, we demonstrated that fangchinoline inhibits the proliferation and metastasis of melanoma cells by suppressing FAK and its downstream signaling pathway. More importantly, we provide a novel mechanism that fangchinoline could be an effective candidate for the treatment of melanoma.

Introduction

Melanoma is a malignant tumor which originates from nerve endoderm. The malignant degree of melanoma is generally high, and the early stage of blood channel metastasis is especially prone to occur (1). The main features of melanoma are: early onset age, tumor growth rate is rapid, easy to occur lymphatic or blood channel metastasis. In general, melanoma is not sensitive to treatments such as chemotherapy, radiotherapy and immunotherapy. The prognosis is usually poor, and statistics show that the average survival time of melanoma is usually less than a year (2).

Focal adhesion kinase (FAK) is a cytoplasmic no receptor protein-tyrosine kinase, belonging to the protein tyrosine kinase superfamily, also called PTK II, FAK is essential for the cell signal transduction, participates in many 'outside-in' and 'inside-out' pathways. FAK can integrate signals from intr-grin, growth factors and mechanical stress, activate the PI3K/Akt and Ras/MAPK pathways, and regulate cell proliferation, apoptosis and metastasis. Besides, FAK is tightly linked to the embryonic development and the occurrence and development of cancer.

Recent studies showed that as a tumor proto-oncogene, the expression and the activity of FAK was increased in many typess of tumors, such as colon, breast, gastric cancer and melanoma. When tumor cells were treated with specific inhibitor of FAK, the growth and invasion of the cells could be significantly inhibited. Phosphorylation of FAK can activate or inhibit a number of downstream pathways, including PI3K/Akt and Ras/MAPK pathways, and regulate cell proliferation, apoptosis and metastasis. Besides, FAK is tightly linked to the embryonic development and the occurrence and development of cancer.

Fangchinoline are widely distributed in nature. It has extensive biological activities, such as enhancing immunity, anti-inflammatory sterilization and anti-atherosclerosis. In recent years, researchers found that fangchinoline has a certain role in the resistance on variety of tumor promoters, but also can inhibit the growth of malignant tumor cells (6,7). In addition, fangchinoline can also induce apoptosis of tumor cells. A variety of experimental studies show that fangchinoline has inhibitory effect on lung, breast, prostate cancer and other tumor cells (8-11). Thus, the antitumor activity of fangchinoline has gained increased attention from researchers. The underlying anticancer mechanism of fangchinoline still needs to be explored further, and the study of fangchinoline on melanoma has not been reported.

In the present study, we report that by inhibiting the phosphorylation of FAK and suppressing its downstream signaling...
pathway, fangchinoline could suppress the growth and metastasis of melanoma cells, thus, we provide new strategies for therapies in melanoma.

Materials and methods

Drugs. Fangchinoline was purchased from the Shenyang Pharmaceutical University (Shenyang, China). Dimethyl sulfoxide (DMSO) was used to dissolve configurations into different concentrations. PF-562271 (Selleck Chemicals LLC, Houston, TX, USA) is a potent ATP-competitive reversible inhibitor selective for recombinant FAK and PYK2 kinase.

Cell culture. HEK 293 (Human embryonic kidney cells, purchased from Shanghai Maisha Biotech Corp., Shanghai, China), A375 (melanoma cells, purchased from ATCC, Manassas, VA, USA; CRL-1619) and A875 (melanoma cells, from Shanghai Maisha Biotech) were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS; Invitrogen), 100 IU/ml penicillin and 100 mg/ml streptomycin (Baomanbio, Shanghai, China), at 37°C in a humidified atmosphere containing 5% CO².

MTT assays. Cells were plated 96-well plates at a density of 1x10⁴ cells/well; 24 h later, the medium was replaced with medium containing DMSO or the indicated concentrations of fangchinoline or 1.5 nM PF-562271 then incubated for 12, 24, 36 and 48 h. At the end of the incubation, the capability of cellular proliferation was measured by MTT assay. The optical densities at 490 nm were measured using a microplate reader.

Flow cytometry. After incubating with the indicated concentrations of fangchinoline for 24 h, the filters were stained with crystal violet (Amresco, Solon, OH, USA) containing a gelatin-coated polycarbonate membrane filter (pore size, 8 mm) for the migration and invasion assays, respectively. Medium without serum was supplemented into the lower well. After 24-h incubation at 37°C with 5% CO², the filters were stained with crystal violet (Amersco, Solon, OH, USA). Five random fields were counted per chamber by using an inverted microscope.

Hoechst 33258 staining. Cells were incubated with DMSO or fangchinoline for 24 h. After incubation, cells were washed then incubated with 10 µg/ml Hoechst 33258 for 5 min at room temperature. Five random fields were counted per chamber by using an inverted microscope.

Annexin V-FITC/PI staining. Following the Annexin V-FITC/PI staining apoptosis detection kit instructions, the specific steps were as follows: cells were washed twice with cold phosphate-buffered saline (PBS), then re-suspended with binding buffer at a concentration of 1x10⁶ cells/ml, adding 5 µl of Annexin V-FITC and 10 µl of PI. The cells were incubated in the dark, at room temperature for 15 min. Finally, adding 400 µl binding buffer to each tube and the apoptosis rate was measured by flow cytometry within 1 h.

Reverse transcription and quantitative real-time PCR. Total RNA of A375 cells after treating with different factors for 24 h were isolated by TRIzol (Invitrogen) according to the manufacturer’s protocol. Complementary DNA was synthesized by reverse transcription of total RNA using an RT reaction kit (Promega, Madison, WI, USA). Real-time PCR was performed according to the manufacturer’s instruction. SYBR Premix Ex Taq (Takara Bio, Tokyo, Japan) was used as a DNA-specific fluorescent dye. The primer sequences were synthesized as shown in Table I.

All the reactions were repeated at least three times. Gene expression levels were calculated relative to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) by using Stratagene Mx3000P software (Stratagene, La Jolla, CA, USA).

Western blot analyses. Whole cell extracts (lysate) were prepared from 1x10⁶ cells in lysis buffer, to determine the expression of protein. A total of 30 µg of proteins from each sample were subjected to 10% SDS-polyacrylamide gels and transferred onto a nitrocellulose membrane. Target proteins were probed with specific antibodies (F-AK (sc-56015), Bax (sc-271195), cyclin D1 (sc-70899), bcl-2 (sc-56015), bax (sc-20067), paxillin (sc-136297) and GAPDH (sc-367714) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Gels were stripped and reprobed with antibodies against GAPDH to assure equal loading.

Table I. The primer sequences used in the present study.

| Name  | Forward primer (5’→3’) | Reverse primer (5’→3’) |
|-------|------------------------|------------------------|
| FAK   | GAGCGTCTAATCCGAGACAGCA| GCGGCTCATCTCCTGTCACAC  |
| Cyclin D1 | CCGAGGAGCTGCTGCAAATGGAG | TGAATCTGTCGGGGGTCTTGCAG |
| Bcl-2 | GGTGAAGCTGGGGGAGATTTG | GCCAGGCATATGGAGTTTCAC  |
| Bax   | AGCTGAGCGAGTGTCTCAAG  | GTCCAATGTCAGCCCATGA   |
| Paxillin | GGAGTCTACCCCTCCACA  | CCACTGTCCTAAGGCTCAAA |
| GAPDH | AGAAGGCTTGGGCTATTG  | AGGGCCATCCACAGCTTTC  |
Figure 1. Fangchinoline inhibits the proliferation of melanoma cells. (A) HEK293, A375 and A875 cells were treated with indicated concentrations of fangchinoline, cells growth was detected by MTT assay. Data are shown as mean ± SEM. (B and C) The inhibition rate of fangchinoline on A375 and A875 cells were detected by MTT, IC₅₀ values were calculated and linear fit curve was drawn with an equation of $y=0.01301x+0.3385$ $R^2=0.8331$ and $y=0.01247x+0.2980$ $R^2=0.8685$. (D) A375 and (E) A875 cells were analyzed by a FACS Vantage flow cytometer with the CellQuest acquisition and analysis software program, the experiment was repeated three times. (F) A375 cells were treated with the indicated concentration of fangchinoline for 24 h, the indicated proteins were detected by western blot analysis. Data are shown as mean ± SEM. **P<0.01 vs. DMSO treated group. (G) A375 cells were treated with the indicated concentration of fangchinoline for 24 h, the indicated mRNA levels were detected by real-time PCR. Data are shown as mean ± SEM. **P<0.01 vs. DMSO treated group.
ShI et al.: FANGCHINOLINE SUPPRESSES MELANOMA

Statistical analysis. The data were analyzed with the SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). The experiments were repeated three times and the data from three independent experiments are expressed as mean ± SD. Statistical significance was set at P<0.05.

Results

Fangchinoline inhibits proliferation of melanoma cells. It has been shown that fangchinoline can inhibit the growth of tumor cells, we examined the different concentrations of fangchinoline on proliferation of HEK293, A375 and A875 cells by MTT assay. MTT assay results showed that the proliferation of cells was suppressed in a concentration-dependent manner of fangchinoline (Fig. 1A). Since the inhibition of fangchinoline on HEK293 cells was weak, the inhibition of it on melanoma cells was stronger. Thus, we infer that fangchinoline may have specific inhibitory effect on tumor cells to a certain extent. Then we learned through a large number of data analysis that fangchinoline inhibited the proliferation of A375 and A875 cells activity with IC50 values of 12.41 and 16.20 µM (Fig. 1B and C). In order to clarify the inhibitory mechanism of fangchinoline on cells proliferation, cell cycle analysis was performed. A375 and A875 cells were exposed to DMSO or indicated concentrations of fangchinoline for 24 h. The results showed that cells were arrested in G1 phase and the percentage of cells in S phase decreased (Fig. 1D and E). The phosphorylation level of FAK was upregulated in the melanoma, and it could be involved in the proliferation of melanoma through several pathways. Thus, we investigated whether fangchinoline can be influenced by the FAK signaling pathway to regulate the proliferation of melanoma cells. Since cyclin D1 is the key regulators in G1 phase of the cell cycle and is one of the downstream proteins of FAK pathway, we examined the expression of it by western blot analysis and real-time PCR (Fig. 1F and G). Results showed that the degree of FAKp-Tyr397 and cyclin D1 decreased significantly after exposure to fangchinoline for 24 h at the indicated concentration. These results indicated that fangchinoline could inhibit proliferation of A375 and A875 cells in a concentration-dependent manner through FAK/cyclin D1.

Fangchinoline promotes apoptosis of melanoma cells. Proliferation and apoptosis can control the growth of cells. Because fangchinoline inhibited the proliferation of melanoma cells, we further examined the effect of fangchinoline on apoptosis. Hoechst 33258 staining assay and Annexin V-FITC/PI staining showed that after treated with fangchinoline for 24 h,
A375 and A875 cell apoptosis was promoted (Fig. 2A-D). Then we detected bcl-2 and bax which are apoptosis-associated proteins by western blot analysis and real-time PCR (Fig. 2E and F). We found that the level of bcl-2 was downregulated by fangchinoline, the expression of bax was upregulated by fangchinoline. This result suggests that fangchinoline was able to regulate the phosphorylation level of FAK and apoptosis related pathways to promote apoptosis of melanoma cells.

Fangchinoline inhibits metastasis of melanoma cells. To study whether fangchinoline was involved in suppressing metastasis of melanoma cells, Transwell assay (with or without Matrigel) were performed (Fig. 3A-D). Results showed that fangchinoline significantly decreased the invasion and migration potential of A375 cells and A875 cells in a dose-dependent manner. It is well known that paxillin is an important protein in the regulation of cell invasion and metastasis in the FAK

Figure 3. Fangchinoline inhibits metastasis of melanoma cells. (A and B) A375 cells were treated with fangchinoline for 24 h; Transwell assay with or without Matrigel was performed. Cells were counted and results represent the mean ± SD of three experiments. **P<0.01 vs. DMSO treated group. (C and D) A375 cells were treated with fangchinoline for 24 h; Transwell assay with or without Matrigel was performed. Cells were counted and results represent the mean ± SD of three experiments. **P<0.01 vs. DMSO treated group. (E and F) A375 cells were treated with the indicated concentration of fangchinoline for 24 h, the indicated proteins and mRNA levels were detected by western blot analysis and real-time PCR. Data are shown as mean ± SEM. **P<0.01 vs. DMSO treated group.
Shi et al.: Fangchinoline suppresses melanoma signaling pathway. Subsequently the protein and mRNA levels of paxillin were detected by western blot analysis and real-time PCR, respectively. With the increasing concentration of fangchinoline the protein and mRNA expression of paxillin was significantly decreased, which implied fangchinoline inhibited the metastasis potential of melanoma cells by inhibiting paxillin.

Fangchinoline suppresses the growth and metastasis potential of A375 cells by inhibiting the phosphorylation of FAK. In order to explore if the inhibitory effect of fangchinoline on growth and metastasis of melanoma cells was achieved through inhibition the phosphorylation of FAK. We added the FAK inhibitor-PF-562 treatment group in our research. MTT assay result showed that after adding the inhibitor of FAK in A375 cells, the growth effect of fangchinoline on A375 cells was not obvious (Fig. 4A). Transwell assay results showed that FAK inhibitors could inhibit the migration of A375 cells. However, when FAK inhibitors and fangchinoline were used together in A375 cells the inhibition of A375 cell migration had no significant difference with the FAK inhibitor treated alone (Fig. 4B). After that we checked the changes of FAKph-Tyr397, FAK, cyclin D1, bcl-2, bax and paxillin in FAK inhibitor group, FAK inhibitor with fangchinoline group and control group (Fig. 4C and D). Western blot analysis and real-time PCR showed that when fangchinoline and FAK inhibitors were combined and applied on A375 cells the effect on these proteins was similar to FAK inhibitors alone application on...
A375 cells. The data showed that the inhibitory effect of fangchinoline on A375 cells was achieved by inhibiting FAK phosphorylation. The above results indicated that fangchinoline could suppress the growth and metastasis of melanoma cells by specially targeting FAKp-Tyr397.

Discussion

FAK can promote the proliferation of tumor cells by regulating the cell cycle and apoptosis. At present, it is believed that FAK could promote the proliferation of tumor cells by increasing the cellular DNA synthesis and accelerating the transformation of G1/S phase. The studies found that the activity of FAK increased significantly in a variety of highly invasive cells (12-14). It was demonstrated that FAK could bind to the death domain kinase receptor interacting protein RIP and inhibit the tumor-suppressing apoptotic function of RIP (15). In addition, FAK was reported to interact with p53 and to inhibit p53 apoptotic activity (16). It was demonstrated that FAK could activate the PI3K/Akt pathway and induce function of NF-kB to achieve the anti-apoptotic function in HL-60 leukemia cells (17). FAK was shown to mediate cell invasion and metastasis through promotion of epithelial-mesenchymal transition (18). Studies showed the importance of FAK activation to enable proliferation of micrometastatic cancer cells disseminated in the lungs (19). In melanoma, when the activity of FAK was inhibited, the growth and metastasis of melanoma were inhibited (3-5,12,20-22).

Fangchinoline is a bisbenzylisoquinoline alkaloid isolated from Radix Stephaniae tetrandrae S. Previous reports showed that, fangchinoline could induce cell cycle arrest, apoptosis and metastasis in cultured cancer cells. Fangchinoline may be a potential drug candidate for the prevention of lung cancer by the downregulation of cellular CDK4, CDK6 and cyclin D1 levels then blocking cell cycle progression (6). Fangchinoline could target PI3K in tumor cells that express PI3K abundantly and inhibit the growth and metastasis ability of SGC7901 cells (23). Studies showed that fangchinoline induced G1/S arrest by modulating expression of p27, PCNA and cyclin D in human prostate carcinoma cancer PC3 cells and tumor xenografts (7,9). Fangchinoline also induced autophagic cell death via p53/strin2/AMPK signaling in human hepatocellular carcinoma cells (24). Reports also indicated that fangchinoline inhibited cell proliferation via Akt/GSK-3β/cyclin D1 signaling and induce apoptosis in MDA-MB-231 breast cancer cells (10,11,25). Researchers pointed out that fangchinoline could achieve the inhibition of lung cancer and glioma role by regulating multiple signaling pathways (26,27).

Many reports pointed out that fangchinoline could inhibit cell proliferation, promote cell apoptosis, inhibit cell metastasis and inhibit tumor angiogenesis to achieve the purpose of inhibiting the occurrence and development of tumors. However, there was no report on whether fangchinoline could play the same role in melanoma cells as in other cancer cells. In the present study, we observed the effect of fangchinoline on different cell line proliferation through the MTT assay. The results showed that fangchinoline inhibited melanoma cell proliferation dose-dependently. The flow cytometry experiment pointed out that fangchinoline could repress the cell cycle from G1 to S phase transformation. The effect of this was through the inhibition of cyclin D1. At the same time we found that apoptosis of fangchinoline could promote the apoptosis of melanoma. In addition, through Transwell experiments we found that fangchinoline regulated the proliferation of melanoma cells, and it could inhibit melanoma cell metastasis through inhibiting paxillin. By detecting the protein level and mRNA level of FAK and FAKp-Tyr397 we found that these functions were likely to be due to the inhibition of fangchinoline by phosphorylation of FAK. We found that when FAK inhibitor was added the inhibition of fangchinoline to melanoma cell growth and metastasis almost disappeared, which confirmed that the inhibitory effect of fangchinoline on growth and metastasis of melanoma cells may be achieved by inhibiting the phosphorylation of FAK in the opposite direction.

In summary, our data clarified that fangchinoline could inhibit the growth and metastasis of melanoma cells by inhibiting FAKp-Tyr397 and suppressing the FAK pathway. Although further in vivo tests are needed to confirm our results, our data can still provide a certain experimental basis for the treatment of melanoma.

References

1. Satow R, Nakamura T, Kato C, Endo M, Tamura M, Batorri R, Tomura S, Murayama Y and Fukami K: ZIC5 drives melanoma aggressiveness by PDGF-D-mediated activation of FAK and STAT3. Cancer Res 77: 366-377, 2016.
2. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA and McCarthy JB: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 165: 881-891, 2004.
3. Frame MC and Serrels A: FAK to the rescue: Activated stroma promotes a 'safe haven' for BRAF-mutant melanoma cells by inducing FAK signaling. Cancer Cell 27: 429-431, 2015.
4. Kolli-Bouhafs K, Sick E, Noulle F, Gies JP, De Mey J and Rondé P: FAK competes for Src to promote migration against invasion in melanoma cells. Cell Death Dis 5: e1379, 2014.
5. Kurenova E, Ucar D, Liao J, Yemema M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN and Cance WG: A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle 13: 2542-2553, 2014.
6. Luo X, Peng JM, Su LD, Wang DY and Yu YJ: Fangchinoline inhibits the proliferation of SPC-A-1 lung cancer cells by blocking cell cycle progression. Exp Ther Med 11: 613-618, 2016.
7. Li D, Lu Y, Sun P, Peng LX, Liu M, Hu LH, Wu WY, Jiang BH, Yang M, Qu XB, et al: Inhibition on proteasome 26 subunit might contribute to the anti-cancer effects of fangchinoline in human prostate cancer cells. PLoS One 10: e014681, 2015.
8. Sun YF and Wink M: Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine 21: 1110-1119, 2014.
9. Wang CD, Huang JG, Gao X, Li Y, Zhou SY, Yan X, Zou A, Chang JL, Wang YS, Yang GX, et al: Fangchinoline induced G1/S arrest by modulating expression of p27, PCNA, and cyclin D in human prostate carcinoma cancer PC3 cells and tumor xenograft. Biosci Biotechnol Biochem 74: 488-493, 2010.
10. Wang CD, Yuan CF, Bu YQ, Wu XM, Wan JY, Zhang L, Hu N, Liu XJ, ZU Y, Liu GL, et al: Fangchinoline inhibits cell proliferation via Akt/GSK-3beta/cyclin D1 signaling and induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J Cancer Prev 15: 769-773, 2014.
11. Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y and Pang D: Fangchinoline induces G1 arrest in breast cancer cells through cell-cycle regulation. Phytother Res 27: 1790-1794, 2013.
12. Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X and Cance WG: Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 15: 357-362, 2005.

13. Sonoda Y, Hada N, Kaneda T, Suzuki T, Ohshio T, Takeda T and Kasahara T: A synthetic glycosphingolipid-induced antiproliferative effect in melanoma cells is associated with suppression of FAK, Akt, and Erk activation. Biol Pharm Bull 31: 1279-1283, 2008.

14. Thapa B, Koo BH, Kim YH, Kwon HJ and Kim DS: Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr106. Biochem Biophys Res Commun 450: 1696-1701, 2014.

15. Karenova E, Xu LH, Yang X, Baldwin AS Jr, Craven RJ, Hanks SK, Liu ZG and Cance WG: Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 24: 4361-4371, 2004.

16. Golubovskaya VM, Finch R and Cance WG: Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem 280: 25008-25021, 2005.

17. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK and Kasahara T: Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 275: 16309-16315, 2000.

18. Golubovskaya VM: Targeting FAK in human cancer: From finding to first clinical trials. Front Biosci (Landmark Ed) 19: 687-706, 2014.

19. Shibue T and Weinberg RA: Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 106: 10290-10295, 2009.

20. Kaneda T, Sonoda Y, Ando K, Suzuki T, Sasaki Y, Ohshio T, Tago M and Kasahara T: Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett 270: 354-361, 2008.

21. Krifa M, El Mesrhi SE, Bentouati N, Pizzi A, Sick E, Chekir-Ghedira L and Rondé P: In vitro and in vivo anti-melanoma effects of pituranthos tortuosus essential oil via inhibition of FAK and Src activities. J Cell Biochem 117: 1167-1175, 2016.

22. Yajima I, Kumasaka MY, Yamanoshita O, Zou C, Li X, Ohgami N and Kato M: GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity. Am J Cancer Res 4: 182-188, 2014.

23. Tian F, Ding D and Li D: Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells. Int J Oncol 46: 2355-2363, 2015.

24. Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G and Feng Y: Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol 164: 731-742, 2011.

25. Xing ZB, Yao L, Zhang QG, Zhang XY, Zhang YX and Pang D: Fangchinoline inhibits breast adenocarcinoma proliferation by inducing apoptosis. Chem Pharm Bull (Tokyo) 59: 1476-1480, 2011.

26. Guo B, Su J, Zhang T, Wang K and Li X: Fangchinoline as a kinase inhibitor targets FAK and suppresses FAK-mediated signaling pathway in A549. J Drug Target 23: 266-274, 2015.

27. Guo B, Xie P, Su J, Zhang T, Li X and Liang G: Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades. Tumour Biol 37: 2709-2719, 2016.